Tags

Type your tag names separated by a space and hit enter

Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae.
Microb Drug Resist. 2019 Nov; 25(9):1357-1364.MD

Abstract

The aim of this study was to investigate the synergy between ceftazidime-avibactam, ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae using the E test MIC:MIC (minimum inhibitory concentration) ratio synergy method. The results were interpreted using fractional inhibitory concentration index (FICI) to describe the effects of antimicrobial combinations in vitro. To assess the clinical significance of each antibiotic combination, the susceptible breakpoint index (SBPI) was calculated for each combination, and within each strain. The FICI method revealed that the most synergistic combinations against carbapenemase-producing K. pneumoniae were ceftazidime-avibactam with ertapenem and ceftazidime-avibactam with fosfomycin. This effect was demonstrated in 47% (9/19) of all tested clinical K. pneumoniae isolates. Considering the effects of all drug combinations in K. pneumoniae harboring blaKPC, blaNDM, and blaOXA-48 genes, we observed that the combination of ceftazidime-avibactam with fosfomycin was the most synergistic in New Delhi metallo-β-lactamase (NDM)-producing K. pneumoniae, and the combination of ceftazidime-avibactam with ertapenem was the most synergistic in K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae. In addition, all tested combinations were synergistic against oxacillinase (OXA)-48-producing K. pneumoniae, except the combination of ceftazidime-avibactam with tigecycline. The SBPI index showed that ceftazidime-avibactam in combination with fosfomycin reduced the MIC to less than the susceptibility breakpoint among all tested carbapenemase-producing K. pneumoniae. Moreover, the combinations of ceftazidime-avibactam with ertapenem, and ceftazidime-avibactam with tigecycline were able to reduce the MIC to less than the susceptibility breakpoint in all KPC- and OXA-48-producing K. pneumoniae.

Authors+Show Affiliations

Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, Bialystok, Poland.Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, Bialystok, Poland.Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, Bialystok, Poland.Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, Bialystok, Poland.Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, Bialystok, Poland.Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Bialystok, Bialystok, Poland.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

31295055

Citation

Ojdana, Dominika, et al. "Activity of Ceftazidime-Avibactam Alone and in Combination With Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella Pneumoniae." Microbial Drug Resistance (Larchmont, N.Y.), vol. 25, no. 9, 2019, pp. 1357-1364.
Ojdana D, Gutowska A, Sacha P, et al. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25(9):1357-1364.
Ojdana, D., Gutowska, A., Sacha, P., Majewski, P., Wieczorek, P., & Tryniszewska, E. (2019). Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae. Microbial Drug Resistance (Larchmont, N.Y.), 25(9), 1357-1364. https://doi.org/10.1089/mdr.2018.0234
Ojdana D, et al. Activity of Ceftazidime-Avibactam Alone and in Combination With Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella Pneumoniae. Microb Drug Resist. 2019;25(9):1357-1364. PubMed PMID: 31295055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae. AU - Ojdana,Dominika, AU - Gutowska,Anna, AU - Sacha,Paweł, AU - Majewski,Piotr, AU - Wieczorek,Piotr, AU - Tryniszewska,Elżbieta, Y1 - 2019/07/11/ PY - 2019/7/12/pubmed PY - 2020/3/21/medline PY - 2019/7/12/entrez KW - carbapenemase-producing K. pneumoniae KW - ceftazidime-avibactam KW - synergy SP - 1357 EP - 1364 JF - Microbial drug resistance (Larchmont, N.Y.) JO - Microb Drug Resist VL - 25 IS - 9 N2 - The aim of this study was to investigate the synergy between ceftazidime-avibactam, ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae using the E test MIC:MIC (minimum inhibitory concentration) ratio synergy method. The results were interpreted using fractional inhibitory concentration index (FICI) to describe the effects of antimicrobial combinations in vitro. To assess the clinical significance of each antibiotic combination, the susceptible breakpoint index (SBPI) was calculated for each combination, and within each strain. The FICI method revealed that the most synergistic combinations against carbapenemase-producing K. pneumoniae were ceftazidime-avibactam with ertapenem and ceftazidime-avibactam with fosfomycin. This effect was demonstrated in 47% (9/19) of all tested clinical K. pneumoniae isolates. Considering the effects of all drug combinations in K. pneumoniae harboring blaKPC, blaNDM, and blaOXA-48 genes, we observed that the combination of ceftazidime-avibactam with fosfomycin was the most synergistic in New Delhi metallo-β-lactamase (NDM)-producing K. pneumoniae, and the combination of ceftazidime-avibactam with ertapenem was the most synergistic in K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae. In addition, all tested combinations were synergistic against oxacillinase (OXA)-48-producing K. pneumoniae, except the combination of ceftazidime-avibactam with tigecycline. The SBPI index showed that ceftazidime-avibactam in combination with fosfomycin reduced the MIC to less than the susceptibility breakpoint among all tested carbapenemase-producing K. pneumoniae. Moreover, the combinations of ceftazidime-avibactam with ertapenem, and ceftazidime-avibactam with tigecycline were able to reduce the MIC to less than the susceptibility breakpoint in all KPC- and OXA-48-producing K. pneumoniae. SN - 1931-8448 UR - https://www.unboundmedicine.com/medline/citation/31295055/Activity_of_Ceftazidime_Avibactam_Alone_and_in_Combination_with_Ertapenem_Fosfomycin_and_Tigecycline_Against_Carbapenemase_Producing_Klebsiella_pneumoniae_ L2 - https://www.liebertpub.com/doi/10.1089/mdr.2018.0234?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -